2025 대한내분비학회 추계학술대회 및 학연산 심포지엄 | 2025.10.30(목) ~ 11.1(토) | 롯데호텔 부산
07:30-07:45 |
![]() |
Beyond HbA1c: Clinical value of DPP-4 inhibitors in TIR and glycemic variability
강선미(순천향의대) |
07:45-08:00 |
![]() |
The benefits of combination therapies including original dapagliflozin 류영상(조선의대) |
07:30-07:45 |
![]() |
Sensational combination for T2DM Patients
김진화(조선의대) |
07:45-08:00 |
![]() |
Optimizing type 2 diabetes management with CGM: Evidence-based strategies for better outcomes 김수경(경상의대) |
07:30-07:45 |
TBD
박정환(한양의대) |
|
07:45-08:00 |
![]() |
Optimizing insulin treatment for your diabetic patients: From insulin initiation to intensification 김규호(가톨릭의대) |
07:30-07:45 |
Benefit of prescribing EZEFENO in mixed dyslipidemia with T2DM_
고정해(인제의대) |
|
07:45-08:00 |
A "new standard" in dyslipidemia treatment 홍준화(을지의대) |
12:20-12:35 |
![]() |
Clinical evaluation of alogliptin; Efficacy and safety in type 2 diabetes
김규리(성균관의대) |
12:35-12:50 |
![]() |
Initiating DPP-4i/SGLT-2i combination: who, when, and why? 이은경(가톨릭의대) |
12:20-12:35 |
![]() |
The evolving landscape of T2D and CKD management with finerenone
정창희(울산의대) |
12:35-12:50 |
![]() |
The new ERA: SGLT2i’s pleiotropic effects 윤재승(가톨릭의대) |
12:30-12:45 |
Exploring semaglutide: in-depth insights into its mechanisms, efficacy, and role in comprehensive diabetes management
양여리(가톨릭의대) |
|
12:45-13:00 |
When and how to start initial combination therapy in T2D 김미진(부산의대) |
12:30-12:45 |
Why SGLT2i comes first for optimal type 2 diabetes treatment
손장원(가톨릭의대) |
|
12:45-13:00 |
![]() |
Benefits of SGLT2 inhibitor combination therapy for the treatment of type 2 diabetes 정인경(경희의대) |